Pharmacy Daily | Cyclophosphamide update

PFIZER Australia has advised health professionals that it’s supporting the efforts of Symbion offshoot Clinect to maintain supply of cyclophosphamide 50mg tablets. Earlier this year Pfizer said that Cycloblastin, used to treat a range of inflammatory illnesses, would be discontinued from 01 October due to a decision by its third party manufacturer to cease production. However last week the company said it’s now working with Clinect to maintain supply of the medicine in the short term via a Special Access Scheme (SAS). Clinect is a healthcare company that assists in bringing to market medicines available overseas to improve patient outcomes in Australia and New Zealand. The SAS will commence when final stocks of Cycloblastin are depleted, allowing clinicians to obtain the product on a case by case basis. Pfizer added that it’s continuing to explore options with Clinect to resume the supply of Cycloblastin tablets in the long term. Enquiries regarding the SAS for cyclphosphamide 50mg tablets can be directed to Symbion SAS on 1300 012 686.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 13